- Home
- DFIN vs AUPH Comparison
DFIN vs AUPH Comparison
Compare DFIN & AUPH Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- DFIN
- AUPH
- Stock Information
- Founded
- DFIN 1983
- AUPH 1993
- Country
- DFIN United States
- AUPH Canada
- Employees
- DFIN N/A
- AUPH N/A
- Industry
- DFIN Other Consumer Services
- AUPH Biotechnology: Pharmaceutical Preparations
- Sector
- DFIN Consumer Discretionary
- AUPH Health Care
- Exchange
- DFIN Nasdaq
- AUPH Nasdaq
- Market Cap
- DFIN 1.4B
- AUPH 1.4B
- IPO Year
- DFIN N/A
- AUPH 1999
- Fundamental
- Price
- DFIN $53.33
- AUPH $11.47
- Analyst Decision
- DFIN Strong Buy
- AUPH Strong Buy
- Analyst Count
- DFIN 3
- AUPH 2
- Target Price
- DFIN $68.67
- AUPH $13.00
- AVG Volume (30 Days)
- DFIN 283.1K
- AUPH 1.9M
- Earning Date
- DFIN 10-30-2025
- AUPH 11-06-2025
- Dividend Yield
- DFIN N/A
- AUPH N/A
- EPS Growth
- DFIN N/A
- AUPH N/A
- EPS
- DFIN 2.79
- AUPH 0.42
- Revenue
- DFIN $755,000,000.00
- AUPH $260,111,000.00
- Revenue This Year
- DFIN N/A
- AUPH $17.33
- Revenue Next Year
- DFIN $4.66
- AUPH $14.31
- P/E Ratio
- DFIN $19.22
- AUPH $27.48
- Revenue Growth
- DFIN N/A
- AUPH 25.59
- 52 Week Low
- DFIN $37.80
- AUPH $6.55
- 52 Week High
- DFIN $69.93
- AUPH $13.54
- Technical
- Relative Strength Index (RSI)
- DFIN N/A
- AUPH 47.42
- Support Level
- DFIN N/A
- AUPH $11.08
- Resistance Level
- DFIN N/A
- AUPH $11.87
- Average True Range (ATR)
- DFIN 0.00
- AUPH 0.62
- MACD
- DFIN 0.00
- AUPH -0.14
- Stochastic Oscillator
- DFIN 0.00
- AUPH 44.06
About DFIN Donnelley Financial Solutions Inc.
Donnelley Financial Solutions Inc is a risk and compliance solutions company. The company provides regulatory filing and deal solutions via its software-as-a-service, technology-enabled services, and print and distribution solutions to public and private companies, mutual funds, and other regulated investment firms. The company operates in four segments: Capital Markets - Software Solutions, Capital Markets - Compliance and Communications Management, Investment Companies - Software Solutions and Investment Companies - Compliance and Communications Management. Its geographical segments are the United States( USA), Europe, Asia, Canada, and others, of which the USA accounts for the vast majority of its total revenue.
About AUPH Aurinia Pharmaceuticals Inc
Aurinia Pharmaceuticals Inc is a biopharmaceutical company focused on delivering therapies to people living with autoimmune diseases with high unmet medical needs. The company developed LUPKYNIS (voclosporin), the first FDA-approved oral therapy for the treatment of adult patients with active lupus nephritis. It is also developing AUR200, a dual inhibitor of B cell activating factor (BAFF) and a proliferation-inducing ligand (APRIL), for the potential treatment of autoimmune diseases.